These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 38542211)
1. Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go. Longo V; Catino A; Montrone M; Montagna ES; Pesola F; Marech I; Pizzutilo P; Nardone A; Perrone A; Gesualdo M; Galetta D Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542211 [TBL] [Abstract][Full Text] [Related]
2. Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor. Zhou P; Fu Y; Tang Y; Jiang L; Wang W PeerJ; 2024; 12():e16923. PubMed ID: 38374950 [TBL] [Abstract][Full Text] [Related]
3. Thorahcic SMARCA4-deficient undifferentiated tumors with ganglioneuroma and enchondroma: implications for SLC7A11 and ARID1A expression: a case report. Kito Y; Kawashima K; Saigo C; Hasegawa M; Nomura S; Mikamo T; Hanamatsu Y; Matsuo Y; Takeuchi T Diagn Pathol; 2022 Feb; 17(1):29. PubMed ID: 35151345 [TBL] [Abstract][Full Text] [Related]
4. Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy. Zhou P; Fu Y; Tang Y; Jiang L; Wang W Lung Cancer; 2024 Mar; 189():107471. PubMed ID: 38306886 [TBL] [Abstract][Full Text] [Related]
5. [Thoracic Xiong Y; Zhang B; Nie LG; Wu SK; Zhao H; Li D; DI JT Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):351-356. PubMed ID: 37042149 [TBL] [Abstract][Full Text] [Related]
6. [Clinical characteristics and prognostic analysis of thoracic SMARCA4-deficient undifferentiated tumor]. Wang XT; Kang Y; Wang HY; Shi WW; Xiao Y; Liu YH; Si JM; Li SL; Jin JJ Zhonghua Yi Xue Za Zhi; 2024 Sep; 104(34):3214-3220. PubMed ID: 39193606 [No Abstract] [Full Text] [Related]
7. Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor. Lin Y; Yu B; Sun H; Zhang H; Hu Z; Zhang Y; Wu Z; Sun S; Zhao X; Yu H; Wu X; Li Y; Wang J; Wang H J Cancer Res Clin Oncol; 2023 Sep; 149(11):8663-8671. PubMed ID: 37115272 [TBL] [Abstract][Full Text] [Related]
8. Thoracic SMARCA4-Deficient Undifferentiated Tumors With Unusual Presentations: A Case Series. Helmink AJ; Alshomrani A; Lauer SR; Yuil-Valdes A Int J Surg Pathol; 2024 Aug; 32(5):992-998. PubMed ID: 37903457 [TBL] [Abstract][Full Text] [Related]
9. Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas. Nambirajan A; Dutta R; Malik PS; Bubendorf L; Jain D Acta Cytol; 2021; 65(1):67-74. PubMed ID: 32854100 [TBL] [Abstract][Full Text] [Related]
11. Usefulness of cell block examination for the cytological diagnosis of thoracic SMARCA4-deficient undifferentiated tumor: A case report. Minoshima A; Sugita S; Segawa K; Aoyama T; Ito M; Daimon F; Takenami T; Kido T; Moriya J; Nishikiori H; Hasegawa T Diagn Cytopathol; 2023 May; 51(5):E149-E154. PubMed ID: 36772934 [TBL] [Abstract][Full Text] [Related]
12. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior. Sauter JL; Graham RP; Larsen BT; Jenkins SM; Roden AC; Boland JM Mod Pathol; 2017 Oct; 30(10):1422-1432. PubMed ID: 28643792 [TBL] [Abstract][Full Text] [Related]
13. Clinicopathological characteristics and treatment outcomes of advanced SMARCA4-deficient thoracic tumors. Wang A; Jin Y; Cao Z; Lu L; Li Z Cancer Med; 2024 Jan; 13(1):e6809. PubMed ID: 38124509 [TBL] [Abstract][Full Text] [Related]
15. Under the Microscope: A Case Report of Thoracic SMARCA4-Deficient Undifferentiated Tumor with Review of the Literature. Mundada M; Mannan KA; Vasu D; Ahmed F; K S Turk Patoloji Derg; 2024; 40(2):128-133. PubMed ID: 38265099 [TBL] [Abstract][Full Text] [Related]
17. Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods. Shi M; Pang L; Zhou H; Mo S; Sheng J; Zhang Y; Liu J; Sun D; Gong L; Wang J; Zhuang W; Huang Y; Chen Z; Zhao Y; Li J; Huang Y; Yang Y; Fang W; Zhang L Lung Cancer; 2024 Jun; 192():107818. PubMed ID: 38763102 [TBL] [Abstract][Full Text] [Related]
18. Gastric SMARCA4-deficient undifferentiated tumor (SMARCA4-UT): a clinicopathological analysis of four rare cases. Zhou P; Fu Y; Wang W; Tang Y; Jiang L Orphanet J Rare Dis; 2024 Jun; 19(1):237. PubMed ID: 38877473 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Yoshida A; Kobayashi E; Kubo T; Kodaira M; Motoi T; Motoi N; Yonemori K; Ohe Y; Watanabe SI; Kawai A; Kohno T; Kishimoto H; Ichikawa H; Hiraoka N Mod Pathol; 2017 Jun; 30(6):797-809. PubMed ID: 28256572 [TBL] [Abstract][Full Text] [Related]
20. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. Ng J; Cai L; Girard L; Prall OWJ; Rajan N; Khoo C; Batrouney A; Byrne DJ; Boyd DK; Kersbergen AJ; Christie M; Minna JD; Burr ML; Sutherland KD Clin Cancer Res; 2024 May; 30(9):1846-1858. PubMed ID: 38180245 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]